|  |  | 2 weeks | 2 weeks | 4 weeks |
---|---|---|---|---|---|
 | Screening | Baseline/Randomization | After 4 interventions |  | Follow-up |
 |  | T0 | T1 |  | T2 |
HTB target (n)a | Â | Â | 4 | 4 | Â |
17-item HAM-D | x | x | x | Â | x |
Medical historyb | Â | x | Â | Â | Â |
HRVc | Â | x | x | Â | x |
Global judgement of efficacy | Â | Â | x | Â | x |
Global judgement of tolerability | Â | Â | x | Â | x |
Adverse eventsd | Â | Â | x | x | x |